MARKET

VKTX

VKTX

Viking Therapeutics Inc
NASDAQ
8.57
+0.17
+2.02%
After Hours: 8.50 -0.07 -0.82% 17:41 01/27 EST
OPEN
8.43
PREV CLOSE
8.40
HIGH
8.72
LOW
8.42
VOLUME
898.43K
TURNOVER
0
52 WEEK HIGH
9.62
52 WEEK LOW
2.020
MARKET CAP
657.22M
P/E (TTM)
-10.7219
1D
5D
1M
3M
1Y
5Y
Viking Therapeutics Completes Patient Enrollment in Phase 2b Clinical Trial of VK2809
Viking Therapeutics Completes Patient Enrollment in Phase 2b Clinical Trial of VK2809
MT Newswires · 01/09 17:40
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), CymaBay Therapeutics (CBAY) and BioCryst (BCRX)
TipRanks · 01/09 16:20
BRIEF-Viking Therapeutics Completes Enrollment In Mid-stage Study Of Vk2809 In NASH Patients
Reuters · 01/09 12:08
Viking Therapeutics Announced Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis
Benzinga · 01/09 12:06
Analyzing Viking Therapeutics's Short Interest
Benzinga · 01/03 15:04
Viking Therapeutics: Booking Profits Following NASH Sympathy Move
Seeking Alpha · 01/03 13:15
5 Most Expensive Health Care Stocks You Should Worry About
Benzinga · 01/03 13:10
Viking Therapeutics sues Ascletis Pharma for stealing trade secrets
Seeking Alpha · 01/03 11:56
More
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for metabolic and endocrine disorders. The Company's lead clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß). The Company is conducting VOYAGE study, a phase II b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). It is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRß for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is engaged in a phase I b clinical trial of VK0214 in patients with X-ALD. Its other clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator (SARM).

Webull offers kinds of Viking Therapeutics Inc stock information, including NASDAQ:VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.